Catalyst Pharmaceuticals, Inc. $CPRX Shares Purchased by WINTON GROUP Ltd

WINTON GROUP Ltd increased its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 546.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 353,529 shares of the biopharmaceutical company’s stock after acquiring an additional 298,862 shares during the quarter. WINTON GROUP Ltd owned approximately 0.29% of Catalyst Pharmaceuticals worth $8,251,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Deerfield Management Company L.P. raised its stake in Catalyst Pharmaceuticals by 72.8% during the third quarter. Deerfield Management Company L.P. now owns 4,974,767 shares of the biopharmaceutical company’s stock worth $98,003,000 after acquiring an additional 2,095,291 shares during the period. Fundsmith LLP raised its stake in Catalyst Pharmaceuticals by 24.2% during the third quarter. Fundsmith LLP now owns 3,363,807 shares of the biopharmaceutical company’s stock worth $66,267,000 after acquiring an additional 654,721 shares during the period. Goldman Sachs Group Inc. raised its stake in Catalyst Pharmaceuticals by 11.9% during the first quarter. Goldman Sachs Group Inc. now owns 3,135,473 shares of the biopharmaceutical company’s stock worth $76,035,000 after acquiring an additional 333,100 shares during the period. Geode Capital Management LLC raised its stake in Catalyst Pharmaceuticals by 0.3% during the fourth quarter. Geode Capital Management LLC now owns 2,900,337 shares of the biopharmaceutical company’s stock worth $67,704,000 after acquiring an additional 10,017 shares during the period. Finally, American Century Companies Inc. raised its stake in Catalyst Pharmaceuticals by 43.8% during the third quarter. American Century Companies Inc. now owns 2,528,186 shares of the biopharmaceutical company’s stock worth $49,805,000 after acquiring an additional 770,198 shares during the period. Institutional investors and hedge funds own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Trading Down 0.1%

NASDAQ CPRX opened at $31.27 on Friday. Catalyst Pharmaceuticals, Inc. has a 52 week low of $19.05 and a 52 week high of $32.56. The stock has a market cap of $3.83 billion, a price-to-earnings ratio of 17.97, a price-to-earnings-growth ratio of 0.95 and a beta of 0.74. The company has a 50-day moving average price of $28.44 and a two-hundred day moving average price of $25.33.

Analyst Ratings Changes

Several equities research analysts recently weighed in on CPRX shares. Citigroup lowered shares of Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their price objective for the stock from $35.00 to $31.50 in a research note on Friday, May 8th. Weiss Ratings upgraded shares of Catalyst Pharmaceuticals from a “buy (b-)” rating to a “buy (b)” rating in a research note on Wednesday. Oppenheimer lowered shares of Catalyst Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Thursday, May 7th. Robert W. Baird lowered shares of Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 7th. Finally, Wall Street Zen cut shares of Catalyst Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, May 9th. Two research analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and six have given a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $32.00.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).